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Abstract
To date, it is widely recognized that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) can exert considerable anti-
tumor effects regarding many types of cancers. The prolonged use of NSAIDs is highly associated with diverse side
effects. Therefore, tailoring down the NSAID application onto individual patients has become a necessary and
relevant step towards personalized medicine. This study conducts the systemsbiological approach to construct a
molecular model (NSAID model) containing a cyclooxygenase (COX)-pathway and its related signaling pathways.
Four cancer hallmarks are integrated into the model to reflect different developmental aspects of tumorigenesis. In
addition, a Flux-Comparative-Analysis (FCA) based on Petri net is developed to transfer the dynamic properties
(including drug responsiveness) of individual cellular system into the model. The gene expression profiles of different
tumor-types with available drug-response information are applied to validate the predictive ability of the NSAID
model. Moreover, two therapeutic developmental strategies, synthetic lethality and microRNA (miRNA) biomarker
discovery, are investigated based on the COX-pathway. In conclusion, the result of this study demonstrates that the
NSAID model involving gene expression, gene regulation, signal transduction, protein interaction and other cellular
processes, is able to predict the individual cellular responses for different therapeutic interventions (such as NS-398
and COX-2 specific siRNA inhibition). This strongly indicates that this type of model is able to reflect the
physiological, developmental and pathological processes of an individual. The approach of miRNA biomarker
discovery is demonstrated for identifying miRNAs with oncogenic and tumor suppressive functions for individual cell
lines of breast-, colon- and lung-tumor. The achieved results are in line with different independent studies that
investigated miRNA biomarker related to diagnostics of cancer treatments, therefore it might shed light on the
development of biomarker discovery at individual level. Particular results of this study might contribute to step further
towards personalized medicine with the systemsbiological approach.
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Introduction
NSAIDs are a class of drugs with distinct chemical
structures. However, they can invoke the common therapeutic
effect: an anti-inflammatory and anti-neoplastic effect [1]. The
key molecular mechanism for this type of anti-tumor drug is the
inhibition of cyclooxygenase (COX) pathway, whose center
components include cyclooxygenase-2 (COX-2), cytosolic
glutathione transferases (GSTM2, 3), and prostaglandin E2
(PGE2). In this pathway, key steps are the enzymatic
conversion from arachidonic acid to prostaglandin G2 (PGG2)
catalyzed by COXs (COX-1 and -2) and subsequent
conversion from PGG2 to prostaglandin H2 (PGH2) catalyzed by
the same enzymes. Each downstream component (including
PGE2, PGI2, PGD2, PGF2 and TXA2) derived from PGH2 has its
unique biological functions to mediate inflammatory responses
and to involve pathophysiological processes [2,3].
To date, it is widely recognized that NSAIDs can exert
considerable anti-tumor effect regarding many types of cancers
such as colon [4], lung [5], prostate [6], head-and-neck [7] and
stomach [8]. It was estimated that the regular use of NSAIDs
for a 10- or 15-year-period can reduce more than 40% of colon
cancer occurrence [9]. Furthermore, it was estimated that in the
USA alone, more than 20 billion aspirin (1st generation NSAID)
tablets are purchased annually, and that more than 1% of the
world population consumes at least one aspirin tablet daily [10].
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Unfortunately, the frequent and prolonged use of NSAIDs has
been associated with different adverse drug effects including
gastritis, abdominal pain, peptic ulcer, gastrointestinal bleeding,
nausea and others [11]. In order to minimize the drug’s side
effects and produce high quality NSAIDs, it has been a chief
interest to identify the NSAID related pathways as well as their
physiological and pathological functions.
Until now, many studies have been conducted to reach the
goal of understanding the molecular mechanism of NSAIDs, for
instance, Dannenberg and Zakim [12] focused on the fact that
the first generation of NSAIDs inhibit COX-1 and COX-2, which
are the key enzymes responsible for the biosynthesis of
prostaglandin from arachidonic acid and they discovered the
diverse biological activities of prostagladins and the
corresponding derived products; Fosslien [13] summarized that
the activity of COX-2, which is undetected in most normal
tissues, can be strongly induced by cytokines, growth factors,
oncogenes, and tumor promoters. Those results indicate the
carcinogenesis contribution of COX-2; subsequently, many
studies discovered that PGE2 can invoke signaling cascades to
perform crosstalk and synergistic effect with diverse signaling
pathways such as epidermal growth factor receptor (EGFR)-
signaling [14], nuclear receptor signaling [15], nuclear factor of
kappa light polypeptide gene enhancer in B-cells (NfκB)-
signaling [16], rat sarcoma (Ras)-mitogen activated protein
kinase (MAPK) signaling [17,18], vascular endothelial growth
factor (VEGFR)-signaling [19], janus kinase/signal transducer
and activator of transcription (JAK-STAT)-signaling [20] and
others.
While the details of NSAIDs molecular mechanisms have
been elucidated, there is need to consider integrative
systematic approaches for reconstruction and mathematical
analyses of large-scale signaling networks related to NSAID.
We want to investigate whether this type of modeling approach
involving extracellular and intracellular signaling mechanisms
might enable a system-level understanding of dynamic
behavior of an individual cellular system. We also intend to
investigate whether modeling of NSAIDs molecular
mechanisms can help tailoring down the NSAID application to
the individual level in order to predict the NSAID effect
according to individuals.
Furthermore, biomarkers are defined as molecular, cellular
or functional measurable parameters that can indicate a
particular genetic, physiological or functional status of a cellular
system [21]. To the present day, no effective in silico approach
has been presented in order to discover high quality miRNA
biomarkers. Therefore, we want to investigate whether the
modeling of miRNA regulation networks could help us step
further towards this goal.
For the first time, this study constructs a molecular model
based on the literature information regarding COX-pathway
and its related pathways. We named it the NSAID model
containing 3874 components and 6398 biochemical reactions.
Furthermore, we developed a Flux-Comparative Analysis
(FCA) to incorporate individual genetic information and different
kinetic parameter-values into the model for simulation. By
applying this approach, we demonstrate the NSAID effect in




The NSAID model contains three layers: a gene-layer, an
RNA-layer and one other layer (includes protein, complex,
metabolite). In the model, each gene takes part in a
corresponding transcription reaction to generate its mRNA,
which in turn produces its protein product via a corresponding
translation. Transcription factors can be translocated into
nucleoplasm to control their target genes by promoting/
repressing transcription reactions (Supplementary Information
S1). Therefore, all three layers in the model are inter-
connected with each other. Table 1 summarizes the model
components and reactions. The center part of this model is the
COX-pathway, where it starts with the COX genes
transcriptions. These lead to the COX protein products that
bind to the available arachidonic acid in the model and catalyze
its conversion into PGG2 under oxygen condition (Figure 1).
PGG2 is then converted into the unstable intermediate PGH2
by the second enzymatic catalyzation of COXs. Afterwards,
different prostaglandins (PGE2, PGI2, PGD2, PGF2 and TXA2)
can be derived from PGH2 with the presence of corresponding
tissue-specific prostaglandin synthases (PTGES, PTGIS,
PTGDS, PTGFS and TBXAS1) [2]. The different prostaglandins
can bind to corresponding receptors and the specific binding
between prostaglandins and their receptors can invoke
signaling cascades that are involved in diverse signaling
pathways to exert cellular functions and signaling responses [3]
(Figure 1). The model contains 20 signaling pathways and the
Supplementary Information S2 lists literature and component
information of each pathway in the model.
Integration of Cancer Hallmarks
Hanahan and Weinberg [22,23] proposed different hallmarks
of cancer and elucidated a framework for a biological
organization principle of cancer developments, which in detail
explains that the human cancer development is a multiple-step
biological malignancy-process. Different independent studies
Table 1. The component/reaction summary of NSAID
model.
Component No. Reaction No.
gene 766 transcription 1145
mRNA 1530 translation 572
protein 1003 decay 1796
miRNA 18 complex-formation 363
compound 44 translocation 995
complex 486 phosphorylation 713
pseudo-object 21 dephosphorylation 212
siRNA 1 activation 240
  miRNA-binding 721
Sum: 3869 Sum: 6757
NSAID Modeling
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show that the deregulation of COX-pathway can contribute to
the tumorigenesis by at least four mechanisms: (1) sustained
angiogenesis [24]; (2) tissue invasion and metastasis [25]; (3)
proliferation [26]; (4) evading apoptosis [27], we have
incorporated these four cancer hallmarks (sustained
angiogenesis, invasiveness and metastasis, proliferation and
apoptosis) into the NSAID model. The hallmark proliferation is
defined in the model as the sum of putative proliferative
biomarkers including upregulation of cell proliferation
(URGCP), antigen identified by monoclonal antibody Ki-67
(MKI67), tripartite motif-containing protein 21 (TRIM21), DNA
topoisomerase 2-alpha (TOP2A), forkhead box M1 (FOXM1),
polo-like kinase 1 (PLK1) and others, which reflects the
proliferative ability of the model and is directly embedded within
the MAPK-, wingless-type MMTV integration site family
(WNT)-, mechanistic target of Rapamycin (MTOR)-, and
hypoxia inducible factor 1 (HIF1)-pathway. The hallmark tissue
invasion is implemented to present in the sum of all matrix
metalloproteinases in the model and therefore symbolizes the
level of invasion and metastasis process and is directly
embedded within the MAPK-, transforming growth factor beta
(TGFbeta)-, insulin-like growth factor 1 receptor (IGF1R)-, and
NfκB-pathway. The hallmark evading apoptosis is defined as
the sum of anti-apoptotic factors over pro-apoptotic factors in
the model to represent the potential for evading apoptosis in
the model and is directly connected within the Death-
Receptor-, IGF1R-, Toll-like Receptor (TLR)- and COX-
pathway. The hallmark sustained angiogenesis is also defined
as the sum of pro-angiogenesis factors over anti-angiogenesis
factors to symbolize the potential for sustaining angiogenesis in
the model and is directly implicated within the VEGF- and
fibroblast growth factor (FGF)-pathway. All four hallmarks are
defined as pseudo component in the model (Table 2). The
mass action law is applied to the equations for integrating
these four hallmarks into the NSAID model (see Materials and
Methods). The objective of this type of modeling is to reflect the
important role of COX-pathway in the cancer development and
to highlight its ability to influence and attribute the
tumorigenesis process in different aspects. Currently, the
influence degrees of different components on hallmarks within
the hallmark equations are not taken into consideration;
Figure 1.  Simplified overview of the NSAID model.  
doi: 10.1371/journal.pone.0072477.g001
NSAID Modeling
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therefore, all coefficients in the hallmark equations are set to 1
(see Materials and Methods).
Validation of Functional Indication of Cancer Hallmarks
In 2003, Denkert and colleagues performed an in vitro study
to investigate the therapeutic inhibition effect between COX-
isoform-specific siRNA and COX-2 selective drug NS-398 in
the human ovarian carcinoma cell line (OVCAR-3) [28]. This
was the first time to show that COX-2 selective drug NS-398
had clear inhibition effects for the OVCAR-3 cell proliferation,
whereas the COX-isoform-specific siRNA did not exert any
proliferation inhibition effect on this cell line. In order to test the
quality of our NSAID model and the implementation of cancer
hallmarks, we initialized the NSAID model with the gene
expression data of the OVCAR-3 cell line (see Materials and
Methods). In this way, we expected that the model should be
able to reflect the dynamic behavior of the OVCAR-3 cell line
during the in silico simulation. Afterwards, we conducted the
Flux-Comparative-Analysis (FCA), which is focused on the flux
comparison between a tumor state (control state) and a
therapeutic intervention state (perturbation state) (see Material
and Methods). In this case, we investigated the state of Tumor
+ COX-2 siRNA vs. Tumor state (CT comparison), and the
state of Tumor + NS-398 vs. Tumor (NT comparison), in order
to validate whether the NSAID model could reveal the
differences of these two types of therapeutic inhibition as
Denkert et al. [28] demonstrated in their study.
The FCA result shows that the hallmark proliferation remains
the same in the CT comparison, whereas in NT comparison,
the hallmark proliferation is reduced to 79.8% of the
proliferation from the tumor state (Figure 2), which indicates
that the NSAID model can alter the inhibition effect between
COX-2 siRNA and drug NS-398 regarding the OVCAR-3 cell
line. The FCA also reveals that both types of inhibitions can
lead to considerable reduction of signaling path, starting from
PGG2 to PGE2, which results in decreasing of signaling
crosstalk of COX-pathway with many other signaling pathways.
However, this type of decrease in signaling crosstalk does not
exert great impact in the model, because the PGE2 functional
dependent receptors EP1-4 are low (P<0.001) expressed in the
OVCAR-3 cell line. Therefore, only targeting COX-2 in
OVCAR-3 cannot reduce the high cellular activities of signaling
pathways such as MAPK-, WNT- and NfκB-pathway (Figure
2A), which leads to the high expression level of several
transcription factors including v-myc myelocytomatosis viral
oncogene homolog (MYC), jun proto-oncogene (JUN), fbj
murine osteosarcoma viral oncogene homology (FOS), and
specificity protein (SP) 1,3. These essential transcription
factors are known to be involved in diverse signaling pathways
including MTOR-, WNT-, and Hedgehog pathway to sustain the
high cellular proliferation. In contrast, the drug NS-398
simultaneously inhibits COX-2, VEGF, interleukin (IL) 1 and
tumor necrosis factor (TNF) [29], which leads to reducing
cellular cycle activity, signal within VEGF-, TLR- and
JAK_STAT pathway and signals transduced by phospholipase
C gamma (PLCG) and PTK2 protein tyrosine kinase 2 (PTK2)
so that the cellular proliferation can be reduced during in silico
simulation (Figure 2B) (The mathematical implementation of
this drug is explained in the Materials and Methods).
Furthermore, the hallmark of evading apoptosis is reduced at
14.4% and 25.8% in the CT and NT comparison respectively,
because in both cases of inhibition, the FCA reveals that
activities of TLR- and Death-Receptor-pathway have been
reduced (Figure 2). The FCA also shows that due to the activity
reductions of the VEGF- and FGF-pathway, the hallmark of
sustained angiogenesis is reduced to 59.8% and 65.6% in both
cases (Figure 2). These results suggest that both COX-2
siRNA and drug NS-398 can successfully reduce the COX-2
cellular function, which is involved in the pathological
processes of evading apoptosis and sustained angiogenesis.
However, the drug NS-398 can exert a better inhibition effect
than the COX-2 siRNA does by reducing both pathological
processes regarding this cancer cell line. The hallmark of
Table 2. Hallmark Implementation.
Hallmark Implementation References (PudMed)
Evading-apoptosis
(EA)
EA = (TNF1:TNFRSF1B + P-IGF1R:IGF1 + P-IGF1R:IGF2 + BCL2L1 + BCL2 +




P = EIF4E + P-MYC:MAX + URGCP + MKI67 + TRIM21 + MYBL2 + TOP2A +




SA = (P-FGFR:FGF + P–KDR_dimer:VEGFC + P–KDR_dimer:FIGF + P–
KDR_dimer:VEGFA + IL8 + GM-CSF + TIMP) / (1 + CD36:THBS1)
18560389,17933680,20010945,21248359,21742222
Tissue-invasion (TI) TI = MMP7 + MMP9 + MMP2 + MMP1 + MMP13 + MMP10 14967450,16680569,11349215,11344033
DR4_5 indicates a component-entity in the model containing DR4 and DR5. P-IGF1R means the phosphorylated form of receptor protein IGF1R and P-IGF1R:IGF1 the
complex of ligand receptor binding. P–KDR_dimer means the phosphorylated form of dimerized receptor KDR. TNF: tumor necrosis factor; TNFRSF1A (B): tumor necrosis
factor receptor superfamily, member 1A (B); IGF1R: insulin-like growth factor 1 receptor; IGF2: insulin-like growth factor 2; BCL2L1: BCL2 like 1; BCL2: B-cell CLL/
lymphoma 2; MCL1: myeloid cell leukemia sequence 1; FAS: Fas (TNF receptor superfamily, member 6); FASLG: Fas ligand (TNF superfamily, member 6); TNFSF10:
tumor necrosis factor (ligand) superfamily; member 10; DR4_5: death receptor 4 and 5; BAX: BCL2-associated X protein; BAK1: BCL2-antagonist/killer 1; PMAIP1:
phorbol-12-myristate-13-acetate-induced protein 1; BBC3: BCL2 binding component 3; EIF4E: eukaryotic translation initiation factor 4E; MAX: MYC associated factor X;
PCNA: proliferating cell nuclear antigen; KDR: kinase insert domain receptor; GM-CSF: granulocyte-macrophage colony-stimulating factor; TIMP: TIMP metallopeptidase
inhibitor; CD36: CD36 molecule; THBS1: thrombospondin 1; MMP: matrix metallopeptidase 3.
NSAID Modeling
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tissue invasion and metastasis remains unchanged in both CT
and NT comparisons.
In 2006, Strillacci and colleagues applied a RNA interference
technique to knock down the overexpressed COX-2 in colon
cancer cell lines (HT-29) and found that this COX-2 knockdown
did not exert any effect on HT-29 cell proliferation [30].
Furthermore, at the same time, Charames and Bapat
conducted siRNA experiment to inhibit the expression level of
COX-2 in HT-29 cell lines and revealed that this type of siRNA
inhibition did not have effect on HT-29 apoptosis [31]. In order
to further validate the hallmarks in the NSAID model, we
initialized the NSAID model with the gene expression data of
the HT-29 cell line (see Materials and Methods) and performed
FCA analysis for the HT-29 cell line of the state of Tumor +
COX-2siRNA state vs. Tumor state (CT2 comparison). The
result shows that the hallmarks of proliferation remained
unchanged, because the low expression of PGE2 cognate
receptor EP1-4 cause the less impact effect of dramatical
signal reduction of COX-pathway in the model, many important
transcription factors including SP3, c-myb viral oncogene
homolog (MYB), GLI family zinc finger (Gli) and catenin
(cadherin-associated protein), beta (CTNNB) involved in
MAPK-, Hedgehog- and WNT pathway are not affected by this
COX-2 siRNA interference in HT-29 cell line. Moreover,
evading apoptosis is only slightly reduced (99.3% of the tumor
state) (Figure 2C), because many caspase (CASP) proteins in
the model maintain a high cellular activity. These results are
qualitatively in agreement with results of both studies of
Strillacci et al. [30] and Charames and Bapat [31]. Based on
the fact that COX-2 siRNA interference cannot affect the
cellular proliferation in OVCAR-3 and HT-29 cancer cell lines,
we would like to suggest the restriction of COX-2 siRNA
interference for cell lines and xenografts that have a low
expression level of EP1-4 receptors. However, this suggestion
should be further verified in future studies.
Analysis of COX Based Synthetic Lethality for Breast,
Colon and Lung Tumor
Synthetic lethality describes the relationship of a gene pair,
when the simultaneous mutations of both genes can lead to
cell death, while the mutation of each gene is still compatible to
the cell viability [32]. This concept of synthetic lethality could
provide essential molecular information for developing high
quality of anti-cancer drugs, which can enhance the on-target
efficiency and reduce the off-target effects to the minimum.
Based on the anti-tumor effect of the COX-pathway, many
preclinical studies have indicated that the treatment by
inhibiting COX-2 (key component of COX-pathway) and a
Figure 2.  Simplified visualization of COX-2 inhibitions within the NSAID model network.  A: Inhibition of COX-pathway via
COX-2 specific siRNA interference. B: Inhibition of COX-pathway via the drug NS-398 (COX-2 selective inhibitor). C: Heatmap
result of FCA includes CT comparison (first row), NT comparison (second row) and CT2 comparison (last row). The color bar is
designed for A, B and C and color ratios of cancer hallmarks are the results of FCA analysis, which is explained in the Materials and
Methods with Figure 5.
doi: 10.1371/journal.pone.0072477.g002
NSAID Modeling
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receptor tyrosine kinase such as EGFR, v-erb-b2 erythroblastic
leukemia viral oncogene homolog 2 (ERBB2), could yield
additive effect, which is far more effective than either single
agent alone [33–35]. Therefore, we aimed to apply the NSAID
model to investigate impact of the COX-based synthetic
lethality with all receptor tyrosine kinases defined in this model
for different tumor types. We utilized the gene-expression data
of 60 tumor cell lines that are provided by the cancer genome
atlas (https://tcga-data.nci.nih.gov) and performed in silico
simulations to investigate the COX-2 based combination
inhibition. These tumor cell lines include 20 breast tumor cell
lines, 20 colon tumor cell lines and 20 lung tumor cell lines
(Supplementary Information S3). All combination-inhibitions of
COX-2 and receptor tyrosine kinases within the NSAID model
were analyzed for each tumor cell line. The analysis method is
based on the FCA. In this case, the control state is the steady
state which the NSAID model reaches during in silico
simulation with the gene-expression data initialization of
corresponding tumor cell lines. The perturbation state is the
steady state which the NSAID model reaches with the same
data initialization and additional combined inhibition of COX-2
and a receptor tyrosine kinase. The readout components of
FCA are the integrated four cancer hallmarks in the model.
Each combination-inhibition (such as COX-2+EGFR and
COX-2+ERBB2) presents a type of therapeutic perturbation for
a tumor cell line.
Angiogenesis is the process of new blood vessel formation
and in the course of solid tumor development, tumor tissue
such as breast, colon and lung becomes highly dependent on
angiogenesis for maintenance and progression [36]. The
combination inhibitions of COX-2 and receptor tyrosine kinases
could achieve more significant reductions of angiogenesis than
single COX-2 inhibition during in silico simulation, especially for
colon and lung tumor cell lines (Figure 3A), where combination
inhibitions of COX-2 lead to less than 30% remaining
angiogenesis processes (68.84% and 43.72% remaining
angiogenesis for single COX-2 inhibition in colon and lung
tumors respectively). These results indicate that the
combination inhibition of COX-pathway and a receptor tyrosine
kinase can dramatically reduce the angiogenesis, which leads
to growth inhibition of colon and lung tumor. These results act
in concert with the study of Tuccillo et al. [37], who examined
the additive effect of the anti-cancer drug-combination of
ZD6474 (a EGFR and VEGFR inhibitor) and SC-236 (a
selective COX-2 inhibitor) on the xenograft models of lung and
colon cancer, and these results are also in agreement with the
study of Mann et al. [33] and Tortora et al. [34]. Both studies
applied the combined treatment for inhibiting COX-2 and
ERBB2, and COX-2 and EGFR to exert the anti-angiogeneic
effect on colon cancer cell lines and xenograft models.
For breast tumor, the combination inhibitions of COX-2 and
receptor tyrosine kinases could reach between 40% and 60%
remaining angiogenesis, which are far better than 81.13%
remaining angiogenesis of a single COX-2 inhibition (Figure
3A). These additive effect suggests that the combined
treatments of COX-2 and receptor tyrosine kinases might be a
effective therapeutic strategy for breast tumor treatment.
However, compared to other two tumors, the breast tumor
shows stronger resistance to COX-2 based combination
inhibitions (Figure 3A). We compared the signal intensity
among pathways in the NSAID model to investigate which
pathways might possess high activity to contribute this type of
inhibition resistance. We found out that under the combination
inhibition, in average, breast tumor cell lines still possess
relatively higher activities (> 1.4 fold) of Hedgehog-pathway
(1.75 fold), EGFR-pathway (1.64 fold), JAK/STAT-pathway
Figure 3.  Effect of the COX-based combined inhibition on cancer hallmarks.  Angiogenesis (A), Evading Apoptosis (B),
Proliferation (C) and Metastasis (D). The blue, red, and yellow columns in each histogram indicates averages of the relative
changes of cancer hallmarks for 20 breast carcinoma samples, 20 colonrectal carcinoma samples, and 20 lung carcinoma samples
respectively. The relative change of each cancer hallmark refers the comparison between therapeutic perturbation state (COX-
based inhibition) and control state (tumor state), which is calculated by the Flux Comparative Analysis (FCA).
doi: 10.1371/journal.pone.0072477.g003
NSAID Modeling
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(1.49 fold), WNT-pathway (1.43 fold), compared to colon tumor
cell lines; while compared to lung tumor cell lines, breast tumor
cell lines possess relatively higher activities (> 1.4 fold) of JAK/
STAT-pathway (1.67 fold), cell-cycle-pathway (1.59 fold),
ERBB-pathway (1.5 fold).
Apoptosis, the process of programmed cell death, is a critical
cellular mechanism for enabling the efficient removal of
superfluous, damaged or infected cells. The disturbances to
the apoptotic machinery can lead to excessive cell survival or
cell death, which can result a number of pathological conditions
including tumorigenesis [38,39]. All combination inhibitions of
COX-2 and receptor tyrosine kinases can reach below 61%
remaining evading apoptosis for these three tumor types.
Especially for the lung cancer, the remaining evading apoptosis
is even below 40% (Figure 3B). Interestingly, in comparison
with average remaining evading apoptosis by single COX-2
inhibition of these three tumor types, the combination
inhibitions of COX-2+ERBB2, COX-2+ERBB3, COX-2+EGFR
and COX-2+PDGFRB (platelet-derived growth factor receptor
beta), show clear additive effect for breast and colon tumors,
whereas for lung tumor, the combination inhibition of
COX-2+EPHB (EPH receptor) and COX-2+FGFR have a clear
additive effect. All other combination inhibitions for these three
tumor types remain almost the same as the single COX-2
inhibition, which indicates no additive therapeutic effect of
those combination inhibitions. Interestingly, the combination
inhibition of COX-2+INSR shows even higher evading
apoptosis than the single COX-2 inhibition. The reason for this
is that the inhibition of INSR strongly reduces the insulin
signaling which leads to decrease of phosphorylated protein
kinase C (PKC). The decrease of active PKC results in a signal
reduction of NfκB-pathway, whose downstream target genes
include different pro-apoptotic ligands and receptors such as
Fas (TNF receptor superfamily, member 6) (FAS), TNF-1,
tumor necrosis factor receptor superfamily, member 1A
(TNFRSF1A).
Proliferation is the cellular process for cell growth and
development. With the sufficient nutrition and suitable micro-
environment, the rate of cellular proliferation becomes stable,
which leads to an increase of cell population under the control
of the normal cellular system. The primary task of cancer
development is to stay with the pathological state of highly
controlled proliferation. Unfortunately, for these three types of
tumors, all combination inhibitions of COX-2 and receptor
tyrosine kinases can only exert very little effect on the
proliferation process, which is implied by the result that
remaining proliferation process is higher than 90% for all those
combination inhibitions. Furthermore, none combination
inhibition does not perform clearly better (reduction 30%;
p<0.05) proliferative inhibition than the single COX-2 inhibition
of corresponding tumor type during in silico simulation (Figure
3C). Only three combination inhibitions showed little
improvement (reduction 4%; p<0.05) in comparison with a
single COX-2 inhibition. They are COX-2+RET (ret proto-
oncogene), COX-2+ERBB2 and COX-2+PDGFRA.
Tissue invasion, also called metastasis, is the primary course
of cancer mortality and is also one of the most pertinent
hallmarks of cancer from a therapeutic perspective [40]. During
the in silico simulation, all combination inhibtions except three
combination inhibitions (COX-2+ERBB2 for breast tumor,
COX-2+ERBB3 for breast tumor and COX-2+EPHA for colon
tumor), do not have any effect on the metastasis. Nor do the
single COX-2 inhibitions have any effect on the metastasis for
the three tumors in the model. The combination inhibitions
COX-2+ERBB2 and COX-2+ERBB3 can exceptionally exert
little effect on the metastasis for breast tumor, which are
reflected by the ~ 98% remaining metastasis after inhibition.
And the combination inhibition COX-2+EPHA can have even
little inhibition effect with reaching ~ 99% remaining metastasis.
MiRNA Regulation on COX Pathway and The Potential
for Biomarker Discovery
In recent years, many studies revealed that miRNAs play
important roles in diverse cellular processes such as
angiogenesis, proliferation, cell cycle and apoptosis, therefore
contribute to the tumorigenesis [41,42]. Some recent studies
provide evidence that the lower expression level of certain
miRNAs (miR-101a and miR-199a) is associated with high
COX-2 expression during different cellular processes [43,44].
We incorporated 18 miRNAs with their relevant validated target
information (Supplementary Information S4) into the NSAID
model, whose targets all include the key component COX-2.
The miRNA modeling approach is introduced in the previous
study [45]. We utilized the published miRNA expression data
for the same three tumor types from cancer genome atlas and
investigated if the overexpression of those miRNAs could yield
satisfactory therapeutic effect with the in silico approach (FCA).
For each miRNA, we created a control state (steady state of
the NSAID model with gene expression data initialization) and
perturbation state (steady state of the NSAID model with the
same initialization and additional 100-fold higher miRNA
expression), and we repeated this FCA of miRNA
overexpression for the same 60 tumor cell lines. The objective
of this FCA is to investigate the system-level influence of each
miRNA when its overexpression represses the commonly
overexpressed COX-2 and additionally reduces the expression
level of other targets to yield the effect of “One Hit Multiple
Targets” [46]. Based on FCA results, we performed the
Wilcoxon signed-rank test for calculating the influence score of
each miRNA for 60 tumor cell lines (see Materials and
Methods), the score shows how the overexpression of miRNA
can exert impact on the model. Afterwards we averaged scores
of miRNAs according to the tumor type (Figure 4. A, B and C).
It is noteworthy that many tumor suppressor miRNAs such
as mir-101, mir-10b, mir-200a, mir-205, mir-23 in breast tumor
have high influence scores (>20) (Figure 4A). For example,
mir-10b is the major contributor for the breast cancer
metastasis [47]; mir-101 is the key regulator of autophagy and
modulates the cancer epigenome [48,49]; mir-205 is
responsible for suppression of cell growth and invasion in
breast tumor [50]. The FCA result reveals that the
overexpressions of those miRNAs have a common inhibition
effect on COX-pathway, which leads to high impact on the
NSAID model. This result is in agreement with the fact of the
important role which this pathway plays during breast cancer
development [51,52].
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Interestingly, we found out that many miRNAs that are
typically upregulated in colon cancer stem cells have low
influence scores (<4) (Figure 4B), such as mir-155 [53], mir-16
[53], mir-17 [54] and mir-21 [55] (Figure 4B). This result implies
that the overexpression effect of these typically uprelated
miRNA in colon cancer cellular system might be saturated,
therefore the further overpression of them could only exert little
impact on the NSAID model. Moreover, this result might also
imply a less significant role of the COX-pathway in colon
cancer stem cells. In lung tumors, only 4 miRNAs (mir-10b,
mir-101, mir-152 and mir-26b) have relatively high influence
scores (13<score<23) (Figure 4C). This result indicates the
tumor suppressor roles of those miRNAs in lung tumor, which
act in concert with the results provided by different independent
studies conducted by Zhang et al. [56] and Arora et al. [57].
The rest of miRNAs with low influence scores (<7) indicate the
saturation of an overexpression effect in the NSAID model as
stated similarly for colon cancers. In addition, we found that
some miRNAs such as mir-10b and mir-21 have extremely high
(>20 score; p=0.0034) and low (<3 score; p=0.0021) influence
scores in all these 60 tumor cell lines respectively. Because of
their putative role as biomarker validated in different
independent studies [58–60], we would like to draw the
conclusion that those miRNAs with extremely high or low
influence scores should be considered as miRNA biomarker of
individual tumor cell lines.
Materials and Methods
Implementation of Cancer Hallmarks
The four cancer hallmarks (sustained angiogenesis, tissue
invasion and metastasis, proliferation and evading apoptosis)
are defined as pseudo components in the NSAID model and
they are also considered as readout component for the Flux
Comparative analysis (explained below). Each of them should
be able to summarize the signal from signaling pathways and
presents a developmental aspect of the cancer cell physiology.
The modeling implementation of these four cancer hallmarks is
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listed below with the literature references and the mass action
law is applied for the integration implementation. Currently, the
influence degrees of components on cancer hallmarks have not
been taken into consideration.
Flux Comparative Analysis (FCA)
The flux of a biochemical reaction defines the mass-flow
from substrates into products. For example, a substrate A is
converted into a product B in a reaction R. For simplicity, let us
denote c[A] and c[B] concentrations of A and B respectively.
The initial concentration of c[A] = m and c[B] = 0. By applying
the mass action law with a kinetic parameter k, after the
reaction R occurs once, the c[B] = m * k and c[A] = (1-m) * k.
Now, the c[B] can describe the quantity of the flux of the
reaction R. In this case, the product B is a readout component
for the implemented model. In this way, we assign all reactions
in the model with the standard rate law, mass-action kinetics, in
order to take the pragmatic solution for model simulation (Table
3).
As the name of this approach says, during simulation, we
compare the flux of the readout component in the implemented
model from a control state with the flux of the same component
from a perturbation state. We use the four cancer hallmarks in
the model as readout components to investigate if any kind of
therapeutic perturbation could influence these readout
components. The goal of this approach is to relatively reveal
the effect of the perturbation state (e.g. drug treatment
condition) versus the control state (e.g. pathological cellular
condition) on the model, in order to predict the therapeutic
effect of different kinds of perturbation. Figure 5A is a model
network with empty signal flux. The Figure 5B and 5C
symbolize the control and perturbation states of the same
model network with the same flux input based on the genetic
information (currently the gene expression data). After the flux
Table 3. Summary of mathematical implementations of
reactions in NSAID model.
Reaction
Biochemical
presentation Kinetic rate law
Parameter
Value
Transcription G → m v = [G] * Ktranscription 0.25
Translation m → P v = [m] * Ktranslation 0.35
Decay S1→ v = [S] * Kdecay 0.1
Complex
Formation
S1 + S2→ S1:S2 v = [S1]* [S2]* Kcomplex 0.7
Translocation S1(A)→ S1(B)




















v = [m] * [miRNA] * Kmi 0.01
G: Gene; m: mRNA; P: Protein; S: Substance. A and B stand for different location.
within the model system reaching steady state, the
corresponding components are analyzed (Figure 5D,
histogram), which shows whether or how this kind of
perturbation could influence the key readout component of the
model. As shown in the Figure 5D, the component c in the
control state has the concentration of 36 (a.u.) and in the
perturbation it has the concentration of 5 (a.u.), so the FCA
result of component c is 0.14. Similarlz, FCA results of
components a, b, d, e and f are 1.0, 0.40, 0.67, 0.62 and 1.0,
respectively (Figure 5D). Therefore, the absolute value of
genetic information is irrelevant for the FCA analysis, only the
data proportionality is essential for this approach. The
simulation procedure is based on the Petri net extension
described in the previous study [45].
Mathematical Implementation of COX-isoform Specific
siRNA and NS-398 Drug Effect
The drug effect of COX-2 specific siRNA is concentration
reduction of COX-2 mRNA, while the drug effect of the drug
NS-398 consists of effects generated from four inhibitors that
promote the protein degradation processes of COX-2, VEGFA,
IL1 and TNF respectively. This type of drug effect
implementation is inspired by the in vitro study of Hidvegi et al.
[61], where the authors successfully demonstrated in a mouse
model that the drug carbamazepine can reduce the alpha-
antitrypsin Z (ATZ) by promoting its degradation, which leads to
reduction of hepatic fibrosis. Both mathematical
implementations are listed in Table 4.
Model Initialization with Gene-Expression Data
The model contains different object types including gene,
RNA (mRNA, miRNA), protein, complex compound and
pseudo-object and each type is associated with a
corresponding Id. For instance, gene- and mRNA-object are
ensembl-id; protein- and compound-object are associated with
uniProt-id and ChEBI-id respectively; miRNA- and miRNA
gene-object are associated with the miRNA accession; other
objects are associated with internal model id. All objects except
the gene object are set to 0. During the simulation process, the
model signal is only generated from the transcriptional level
and forwarded to the translational level. Afterwards, the signal
can be propagated to the rest of model.
The initialization procedure is preformed according to
ensembl-id of gene objects in the model; all gene objects in the
model are iteratively assigned with a corresponding gene
expression value according to this Id. Since the value of gene
expression data from Cancer Genome Atlas is log-ratio, we
have to modify the data by exponentiation to retrieve originally
measured gene expression values, because negative log-ratio
is not suitable for Petri net simulation. Afterwards the
aforementioned initialization procedure (pseudo-source code)
is applied to initialize the NSAID model.
Pseudo-source Code:
1. m ← signaling model
2. Initialize(m){
3. if gene expression data is available{
4. gene-entities ← m.getAllGene_Entities()
5. for gene-entity in gene-entities{
NSAID Modeling
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6. set gene-entity with data according to the Ensembl id
7. }
8. }
9. if miRNA expression data is available{
10. miRNA-entities ← m.getAllmiRNA_Entities()
11. for miRNA-entity in miRNA-entities{
12. set miRNA-entities with data according to the miRNA id
13. }
14. }
15. set all other entities in the model to zero.
16. }
17. simulate(m){ # signal flux propagation process on the
Petri net extension [45]
18. }
Calculation of the miRNA Influence Score
Suppose the model having n components and Cx (1 < =x<=n)
is defined as the concentration of one model component. Let
us denote the arrays C = [C1, C2, C3 … Cn] and C' = [C'1, C'2,
C'3 … C'n] are concentrations of all model components in the
control state and perturbation state respectively, with regards
to the FCA analysis. The p-value (P) calculated by the
Wilcoxon signed-rank test(C, C') implies the system-level
impact between model components in both states due to the
miRNA regulation. (It is noteworthy that p-value calculated in
this way should not be considered a possibility of obtaining a
statistical test for acceptance or rejection of null hypothesis.)
miRNA influence score (MIS) = (-1) * log(P, 10)
Figure 5.  Visualization of the Flux-Comparative-Analysis.  A: empty flux state of model network; B: control state of model
network; C: perturbation state (drug inhibition) of model network. D: the comparison of model components between control state and
perturbation state. The mathematical implementation of both states in the model is described.
doi: 10.1371/journal.pone.0072477.g005
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Model Availability
The NSAID model is available under the ftp://
138.245.80.137/NSAID_model.xml in the form of XML.
Discussion and Conclusion
The general aim of this study is to assess the feasibility as to
whether the molecular-based model construction can be
applied for the purpose of therapeutic development including
new potential targets identification and high quality biomarker
discovery. Thus, in this study the first molecular NSAID model
was introduced, whose construction is based on literature
references regarding the COX-pathway and its related
pathways. This model integrates four cancer hallmarks to
realize a biological organization principle for tumorigenesis,
which is a multiple-step process in human cells [22,23]. Each
cancer hallmark in the NSAID model should reflect a
corresponding developmental aspect of cellular malignant
transformation. This study has employed the data from different
in-vitro studies to validate functional indications of these cancer
hallmarks and reached concert with the results of those in-vitro
studies [28,30,31]. In addition, we propose a criterion for
application-restriction of COX-isoform specific siRNA
interference in tumor cell lines. The result also indicates that
the NSAID model could inherit the dynamic behavior of
corresponding tumor cellular systems and react with a similar
response when facing the therapeutic intervention (siRNA
interference and NS-398 drug), which might serve as “Virtual
Patient” for prediction of therapeutic responses from an
individual tumor cell line.
By applying the NSAID model, we tried to explore the novel
concept of synthetic lethality related to the key component
(COX-2) of COX-pathway for 60 cell lines of breast-, colon- and
lung tumor. Many in-vitro and in-vivo studies provided evidence
that the combined treatment by inhibiting the key component of
COX-pathway and a relevant receptor tyrosine kinase such as
EGFR and ERBB2, could yield significant additive therapeutic
effect. Our in silico approach reveals that this type of combined
inhibition (COX-2 and a receptor tyrosine kinase) could reach
Table 4. The difference of mathematical implementation of
different states for FCA analysis.




v = [COX-2(mRNA)] *
Ktranslation
NT Comparison Tumor + NS-398 State Tumor State
Kinetic Rate Law
v = [COX-2(Protein)]* Kdecay*
[Inhibit1]
v = [COX-2(Protein)]* Kdecay
 
v = [VEGF(Protein)]* Kdecay*
[Inhibit2]
v = [VEGF(Protein)]* Kdecay
 
v = [IL1(Protein)]* Kdecay*
[Inhibit3]
v = [IL1(Protein)]* Kdecay
 
v = [TNF(Protein)]* Kdecay*
[Inhibit4]
v = [TNF(Protein)]* Kdecay
The effect of drug NS-398 is now composed of the effect of inhibit1-4.
much better angiogenesis reduction than a single COX-2
inhibition for 40 cell lines of both colon- and lung-tumors, which
reaches an agreement with different independent in-vitro
studies [33–35,37]. In addition, we pointed out that the additive
effect of combined inhibition on breast tumor should be
validated by follow-up studies.
Furthermore, we integrated 18 miRNAs into the NSAID
model in order to investigate miRNA regulation impact on the
model system. Through the influence-score analysis of miRNA,
we drew the conclusion that miRNAs with a higher influence
scores have higher possibility to be tumor suppressor miRNA
in the corresponding tumor, while miRNAs with lower influence
scores have a higher possibility to be oncogenic miRNAs.
Those miRNAs with extremely high or low influence scores are
proposed to be considered a miRNA biomarker. This result of
in silico biomarker discovery is in line with recent independent
studies [58–60]. This influence-score analysis might shed light
on the development of an in silico approach for biomarker
identification at individual level. Many recent studies provide
evidence about the deregulated expression profiling of miRNA
in diverse cancers and elucidate that deregulation of multiple
miRNAs belongs to the common scenario in cancers
[41,62,63]. Therefore, the biomarker of a group miRNAs with
similar functionalities should be more meaningful and
significant than the biomarker of a single miRNA. Based on this
fact, it is possible to extend this current in silico approach to
identify group-wise miRNAs with extreme scores to define the
group-wise miRNA biomarker. However, the exact procedure is
still under investigation.
Many studies introduced mathematical models with the
application of Flux-Balanced analysis and Elementary-Flux
Modes [64–66]. These types of applications do not take into
consideration the fact of dynamic properties which describe the
physiological, developmental and pathological processes for a
cellular system. In contrast, this study introduces the Flux-
Comparative-Analysis (FCA) to combine the genetic input (e.g.
Gene-expression data), network structure (NSAID model) and
kinetic parameters of biochemical reactions to order to reflect
the core aspects of cellular malignancy development and
predict the drug effect and clinical outcome. The satisfactory
results imply that based on mass action law the NSAID model
could reach the certain approximation in order to represent the
dynamics of an individual cellular system with sufficient
accuracy. However, the currently applied kinetic parameters
are based on the empirical experience and takes into
consideration kinetic parameter information listed by the study
of Papin et al. [67]. Future studies should put emphasis on
detecting and measuring kinetic parameter values under
different environmental conditions in order to define specific
interval value with regard to different types of biochemical
reactions.
Although the construction of the current NSAID model is
based on literature information, there are still many limitations
on it, for instance, in the model the concentrations of many
metabolites including ADP, H2O, Orthophosphate and others,
are fixed in order to prevent the signal drop-down within
signaling pathways when those metabolic byproducts are
running out. For all defined phosphorylation reactions in the
NSAID Modeling
PLOS ONE | www.plosone.org 11 August 2013 | Volume 8 | Issue 8 | e72477
model, we do not consider the functional difference between
different phosphorylated sites within the same proteins.
Furthermore, the biological functions among different paralogs
such as ERK1 and ERK2, have not been considered either.
Different studies show that epigenetics plays an important role
in cancer biology [68,69], for instance, DNA hypermethylation
and hypomethylation can be correlated with diagnosis and
prognosis of cancer treatment [70–72]. However, to the
present, it is still not clear how to efficiently translate those
specific epigenetic information into a systemsbiological model.
Currently, the different influence degrees of model components
that act directly on the cancer hallmarks have not been
considered. Future studies should put emphasis on this point to
improve the cancer hallmark integration by recruiting cancer
patients to further investigate the major NSAID drug effect and
side effect with the application of this model.
Finally, the tumour-xenograft model represents the current
standard for preclinical testing of anticancer agents; however,
this type of model has too many limitations to remain an
acceptable gateway to clinical trials [73]. This study gives a
systemsbiological application-example indicating that a
molecular based model containing biological information
related to gene expression, gene regulation, protein interaction,
signal transduction and other cellular processes, can lead to
prediction of systems-level behavior of cellular system
underlying an individual cell line (or patient). Despite mentioned
limitations, the NSAID model with FCA might present an
alternative for preclinical testing of anticancer agents related to
COX-pathway to reduce expenditure of time, expenses and
technical challenges.
Supporting Information
Information S1.  A Modeling Example for the NSAID Model.
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